Insilico, Tenacia expand AI CNS pact in deal worth up to $94.75M
CURRENT BRIEF VERSION: Insilico Medicine has expanded its central nervous system drug discovery collaboration with Tenacia Biotechnology, adding a second AI-enabled program that could bring the deal’s new value to as much as $94.75 million. The companies said March 26 that the broadened agreement builds on a March 2025 partnership focused on blood-brain barrier-penetrant small molecules for neurological disease. Under the updated terms, Insilico and Tenacia will use Insilico’s Pharma.AI platform to advance an additional candidate to the preclinical candidate stage, with Insilico eligible for near-term and milestone payments. Tenacia is a Bain Capital-backed neuroscience company founded in 2022, while Insilico has been positioning itself as a clinical-stage AI drug discovery company with multiple partnered and internal programs. (prnewswire.com)
Why it matters: For veterinary professionals, this isn’t an animal health deal, but it’s another signal that AI-enabled CNS discovery is moving from concept to repeat business. Neurology remains one of the harder areas in both human and veterinary medicine, in part because finding molecules that cross the blood-brain barrier is a persistent challenge. A collaboration expanding after its first year suggests the partners see enough early progress to justify a second program, and it reflects a broader industry push to use AI to shorten discovery timelines, prioritize targets, and reduce attrition before clinical development. That signal is reinforced by Insilico’s separate multibillion-dollar collaboration with Eli Lilly, which gives Lilly exclusive global rights to develop, manufacture, and commercialize certain Insilico preclinical oral candidates for selected indications and includes additional Lilly-selected R&D programs run through Pharma.AI. Insilico has publicly argued its platform can move programs from target to drug candidate in roughly 12 to 18 months, faster than traditional timelines, though those efficiency claims still need to translate into durable clinical success across the field. (prnewswire.com; PharmaShots)
What to watch: Watch for disclosure of the target, preclinical candidate timing, and whether this CNS expansion is followed by more platform-style partnerships after Insilico’s newly announced $2.75 billion Lilly collaboration, which includes a $115 million upfront payment, milestone potential, and tiered royalties on future sales. (wtbx.com; PharmaShots)